Lixte Biotechnology (NASDAQ:LIXT) Releases Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) issued its quarterly earnings data on Monday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.

Lixte Biotechnology Price Performance

NASDAQ LIXT traded down $0.02 during trading hours on Monday, hitting $1.29. 17,957 shares of the company’s stock traded hands, compared to its average volume of 317,816. Lixte Biotechnology has a 52-week low of $1.02 and a 52-week high of $4.40. The company has a market capitalization of $2.90 million, a PE ratio of -0.75 and a beta of 0.19. The firm’s 50-day moving average is $1.81 and its 200-day moving average is $1.89.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.